Casdin Capital, LLC Q2 2016 Filing
Filed August 15, 2016
Portfolio Value
$100.5B
Holdings
25
Report Date
Q2 2016
Filing Type
13F-HR
All Holdings (25 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SG7SAGE THERAPEUTICS INC | 293,500 | $8.8B | 8.80% | Call |
| 2 | —SPARK THERAPEUTICS INC | 162,500 | $8.3B | 8.27% | |
| 3 | AGIOAGIOS PHARMACEUTICALS INC | 187,500 | $7.9B | 7.82% | |
| 4 | —FOUNDATION MEDICINE INC | 390,000 | $7.3B | 7.24% | |
| 5 | GBTUSDGLOBAL BLOOD THERAPEUTICS IN | 430,000 | $7.1B | 7.10% | |
| 6 | —LOXO ONCOLOGY INC | 300,000 | $7.0B | 6.92% | |
| 7 | 2L9BLUEPRINT MEDICINES CORP | 340,000 | $6.9B | 6.85% | |
| 8 | —BLUEBIRD BIO INC | 122,500 | $5.3B | 5.28% | |
| 9 | EVHEVOLENT HEALTH INC | 239,500 | $4.6B | 4.58% | |
| 10 | ALNYALNYLAM PHARMACEUTICALS INC | 72,500 | $4.0B | 4.00% | |
| 11 | —KITE PHARMA INC | 72,500 | $3.6B | 3.61% | |
| 12 | —GENMARK DIAGNOSTICS INC | 415,000 | $3.6B | 3.59% | |
| 13 | VYGRVOYAGER THERAPEUTICS INC | 322,500 | $3.5B | 3.53% | |
| 14 | —EPIZYME INC | 340,000 | $3.5B | 3.47% | |
| 15 | CTMXCYTOMX THERAPEUTICS INC | 234,179 | $2.4B | 2.38% | |
| 16 | DC4DEXCOM INC | 30,000 | $2.4B | 2.37% | Put |
| 17 | —MYOKARDIA INC | 179,029 | $2.2B | 2.21% | |
| 18 | CLVSEURCLOVIS ONCOLOGY INC | 150,000 | $2.1B | 2.05% | |
| 19 | —IGNYTA INC | 375,000 | $2.0B | 2.02% | |
| 20 | —AVEXIS INC | 45,000 | $1.7B | 1.70% | |
| 21 | —TESARO INC | 20,000 | $1.7B | 1.67% | |
| 22 | XBISPDR SERIES TRUST | 30,000 | $1.6B | 1.61% | Put |
| 23 | BMYBRISTOL MYERS SQUIBB CO | 21,000 | $1.5B | 1.54% | |
| 24 | —SYROS PHARMACEUTICALS INC | 50,000 | $908.0M | 0.90% | |
| 25 | —MEDGENICS INC | 85,000 | $472.0M | 0.47% |